JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Search

United Therapeutics Corp

Gesloten

SectorGezondheidszorg

569.06 0.53

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

562.69

Max

571.69

Belangrijke statistieken

By Trading Economics

Inkomsten

26M

364M

Verkoop

-9.3M

790M

K/W

Sectorgemiddelde

20.568

60.328

Winstmarge

46.102

Werknemers

1,400

EBITDA

61M

524M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+12.07% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.7B

25B

Vorige openingsprijs

568.53

Vorige sluitingsprijs

569.06

Nieuwssentiment

By Acuity

50%

50%

157 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

United Therapeutics Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 apr 2026, 23:08 UTC

Winsten
Belangrijke Marktbewegers

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 apr 2026, 23:48 UTC

Marktinformatie

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 apr 2026, 23:42 UTC

Marktinformatie

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 apr 2026, 23:34 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 apr 2026, 23:30 UTC

Marktinformatie

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 apr 2026, 23:08 UTC

Marktinformatie

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 apr 2026, 22:42 UTC

Marktinformatie

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 apr 2026, 22:10 UTC

Winsten

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 apr 2026, 21:56 UTC

Winsten

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 apr 2026, 21:44 UTC

Winsten

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 apr 2026, 21:43 UTC

Winsten

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 apr 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 apr 2026, 20:39 UTC

Winsten

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer Vergelijking

Prijswijziging

United Therapeutics Corp Prognose

Koersdoel

By TipRanks

12.07% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 635.62 USD  12.07%

Hoogste 705 USD

Laagste 519 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor United Therapeutics Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

10

Buy

4

Hold

0

Sell

Technische score

By Trading Central

292.345 / 309.245Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

157 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat